Myelin, copper, and the cuprizone model of schizophrenia

Frontiers in Bioscience - Scholar

Volumn 3 S, Issue 1, 2011, Pages 23-40

  Herring, Nicole R ^a   Konradi, Christine ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Copper; Cuprizone; Myelin; Oligodendrocytes; Prefrontal cortex; Review; Schizophrenia; White Matter

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); BRAIN DERIVED NEUROTROPHIC FACTOR; CERULOPLASMIN; COPPER; COPPER ZINC SUPEROXIDE DISMUTASE; CUPRIZONE; CYTOCHROME C OXIDASE; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; DOPAMINE BETA MONOOXYGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMIC ACID; METALLOPROTEIN; MYELIN; MYELIN ASSOCIATED GLYCOPROTEIN; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NEU DIFFERENTIATION FACTOR; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PROTEOLIPID PROTEIN; REELIN; UNSPECIFIC MONOOXYGENASE;

AGING; APTITUDE; ARTICLE; ATTENTION; BEHAVIOR CHANGE; BIPOLAR DISORDER; BRAIN FUNCTION; CELL FUNCTION; CELL REGENERATION; CELL STRUCTURE; CENTRAL NERVOUS SYSTEM; COGNITION; COGNITIVE DEFECT; COPPER METABOLISM; DEMYELINATION; ELECTRIC ACTIVITY; EMBRYO DEVELOPMENT; ENDOPHENOTYPE; ENERGY METABOLISM; ENVIRONMENTAL IMPACT; EXECUTIVE FUNCTION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE EXPRESSION; GRAY MATTER; HUMAN; INTELLECT; INTELLIGENCE QUOTIENT; LEARNING; LEUKODYSTROPHY; MAJOR DEPRESSION; MEMBRANE DEPOLARIZATION; MENKES SYNDROME; MULTIPLE SCLEROSIS; MYELIN DEFICIENCY; MYELINATION; NONHUMAN; OLIGODENDROGLIA; PREFRONTAL CORTEX; PROTEIN FUNCTION; PROTEIN METHYLATION; QUALITY OF LIFE; SCHIZOPHRENIA; SOCIAL DISABILITY; SUBVENTRICULAR ZONE; SUPERIOR FRONTAL GYRUS; WHITE MATTER; WILSON DISEASE; WORKING MEMORY; ANIMAL; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DEMYELINATING DISEASE; DISEASE MODEL; DRUG EFFECT; EVOLUTION; METABOLISM; MOUSE; MYELIN SHEATH; PATHOLOGY; PHYSIOLOGY; REVIEW;

RODENTIA;

ANIMALS; BIOLOGICAL EVOLUTION; COPPER; CUPRIZONE; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; HUMANS; MICE; MYELIN SHEATH; OLIGODENDROGLIA; SCHIZOPHRENIA;

EID: 79955969407     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: None     Document Type: Article

References (235)

1. N. J. Allen and B. A. Barres: Neuroscience: Glia - more than just brain glue. Nature 457, 675-7 (2009)
2. R. H. Miller: Regulation of oligodendrocyte development in the vertebrate CNS. Prog Neurobiol 67, 451-67 (2002) (Pubitemid 35232446)
3. J. L. Salzer: Nodes of Ranvier come of age. Trends Neurosci 25, 2-5 (2002) (Pubitemid 34093771)
4. I. Vabnick and P. Shrager: Ion channel redistribution and function during development of the myelinated axon. J Neurobiol 37, 80-96 (1998) (Pubitemid 28453387)
5. M. N. Rasband and J. S. Trimmer: Developmental clustering of ion channels at and near the node of Ranvier. Dev Biol 236, 5-16 (2001)
6. R. D. Fields and B. Stevens-Graham: New insights into neuron-glia communication. Science 298, 556-62 (2002)
7. D. L. Sherman and P. J. Brophy: Mechanisms of axon ensheathment and myelin growth. Nat Rev Neurosci 6, 683-90 (2005) (Pubitemid 43160317)
8. R. D. Fields: White matter in learning, cognition and psychiatric disorders. Trends Neurosci 31, 361-70 (2008)
9. Z. Nagy, H. Westerberg and T. Klingberg: Maturation of white matter is as sociated with the development of cognitive functions during childhood. J Cogn Neurosci 16, 1227-33 (2004) (Pubitemid 39274449)
10. S. L. Fryer, L. R. Frank, A. D. Spadoni, R. J. Theilmann, B. J. Nagel, A. D. Schweinsburg and S. F. Tapert: Microstructural integrity of the corpus callosum linked with neuropsychological performance in adolescents. Brain Cogn 67, 225-33 (2008)
11. C. Liston, R. Watts, N. Tottenham, M. C. Davidson, S. Niogi, A. M. Ulug and B. J. Casey: Frontostriatal microstructure modulates efficient recruitment of cognitive control. Cereb Cortex 16, 553-60 (2006)
12. C. K. Tamnes, Y. Ostby, K. B. Walhovd, L. T. Westlye, P. Due-Tonnessen and A. M. Fjell: Intellectual abilities and white matter microstructure in development: A diffusion tensor imaging study. Hum Brain Mapp (epub 2010)
13. B. T. Gold, D. K. Powell, L. Xuan, Y. Jiang and P. A. Hardy: Speed of lexical decision correlates with diffusion anisotropy in left parietal and frontal white matter: evidence from diffusion tensor imaging. Neuropsychologia 45, 2439-46 (2007) (Pubitemid 46946889)
14. V. J. Schmithorst, M. Wilke, B. J. Dardzinski and S. K. Holland: Cognitive functions correlate with white matter architecture in a normal pediatric population: a diffusion tensor MRI study. Hum Brain Mapp 26, 139-47 (2005) (Pubitemid 41434663)
15. S. N. Niogi and B. D. McCandliss: Left lateralized white matter microstructure accounts for individual differences in reading ability and disability. Neuropsychologia 44, 2178-88 (2006) (Pubitemid 43993996)
16. T. Klingberg: Development of a superior frontalintraparietal network for visuo-spatial working memory. Neuropsychologia 44, 2171-7 (2006) (Pubitemid 43993994)
17. T. Klingberg, M. Hedehus, E. Temple, T. Salz, J. D. Gabrieli, M. E. Moseley and R. A. Poldrack: Microstructure of temporo-parietal white matter as a basis for reading ability: evidence from diffusion tensor magnetic resonance imaging. Neuron 25, 493-500 (2000)
18. S. L. Bengtsson, Z. Nagy, S. Skare, L. Forsman, H. Forssberg and F. Ullen: Extensive piano practicing has regionally specific effects on white matter development. Nat Neurosci 8, 1148-50 (2005) (Pubitemid 43348132)
19. K. L. Hyde, R. J. Zatorre, T. D. Griffiths, J. P. Lerch and I. Peretz: Morphometry of the amusic brain: a two-site study. Brain 129, 2562-70 (2006) (Pubitemid 44522090)
20. P. G. Nestor, M. Kubicki, K. M. Spencer, M. Niznikiewicz, R. W. McCarley and M. E. Shenton: Attentional networks and cingulum bundle in chronic schizophrenia. Schizophr Res 90, 308-15 (2007) (Pubitemid 46188517)
21. H. Takeuchi, Y. Taki, Y. Sassa, H. Hashizume, A. Sekiguchi, A. Fukushima and R. Kawashima: White matter structures associated with creativity: Evidence from diffusion tensor imaging. Neuroimage (epub 2010)
22. M. H. Teicher, N. L. Dumont, Y. Ito, C. Vaituzis, J. N. Giedd and S. L. Andersen: Childhood neglect is associated with reduced corpus callosum area. Biol Psychiatry 56, 80-5 (2004) (Pubitemid 38844783)
23. B. I. Roots: The phylogeny of invertebrates and the evolution of myelin. Neuron Glia Biol 4, 101-9 (2008)
24. D. K. Hartline and D. R. Colman: Rapid conduction and the evolution of giant axons and myelinated fibers. Curr Biol 17, R29-35 (2007) (Pubitemid 46027580)
25. R. Schweigreiter, B. I. Roots, C. E. Bandtlow and R. M. Gould: Understanding myelination through studying its evolution. Int Rev Neurobiol 73, 219-73 (2006) (Pubitemid 43776543)
26. D. H. Rowitch: Glial specification in the vertebrate neural tube. Nat Rev Neurosci 5, 409-19 (2004) (Pubitemid 38568501)
27. W. D. Richardson, N. Kessaris and N. Pringle: Oligodendrocyte wars. Nat Rev Neurosci 7, 11-8 (2006) (Pubitemid 41828927)
28. M. Cayre, P. Canoll and J. E. Goldman: Cell migration in the normal and pathological postnatal mammalian brain. Pr og Neurobiol 88, 41-63 (2009)
29. D. M. McTigue and R. B. Tripathi: The life, death, and replacement of oligodendrocytes in the adult CNS. J Neurochem 107, 1-19 (2008)
30. B. Menn, J. M. Garcia-Verdugo, C. Yaschine, O. Gonzalez-Perez, D. Rowitch and A. Alvarez-Buylla: Origin of oligodendrocytes in the subventricular zone of the adult brain. J Neurosci 26, 7907-18 (2006) (Pubitemid 44315160)
31. S. Bava, R. Thayer, J. Jacobus, M. Ward, T. L. Jernigan and S. F. Tapert: Longitudinal Characterization of White Matter Maturation During Adolescence. Brain Res (epub 2010)
32. M. R. Asato, R. Terwilliger, J. Woo and B. Luna: White Matter Development in Adolescence: A DTI Study. Cereb Cortex (epub 2010)
33. P. L. Yakovlev and A. R. Lecours: The myelogenetic cycles of regional maturation of the brain. In: Regional Development of the Brain in Early Life. Ed A. Minkowski. Blackwell Scientific Publications, Oxford (1967)
34. K. Powell: Neurodevelopment: how does the teenage brain work? Nature 442, 865-7 (2006) (Pubitemid 44285927)
35. G. Bartzokis, M. Beckson, P. H. Lu, K. H. Nuechterlein, N. Edwards and J. Mintz: Age-related changes in frontal and temporal lobe volumes in men: a magnetic resonance imaging study. Arch Gen Psychiatry 58, 461-5 (2001) (Pubitemid 32411326)
36. J. I. O'Riordan: Central nervous system white matter diseases other than multiple sclerosis. Curr Opin Neurol 10, 211-4 (1997) (Pubitemid 27352973)
37. C. Theda, A. B. Moser, J. M. Powers and H. W. Moser: Phospholipids in X-linked adrenoleukodystrophy white matter: fatty acid abnormalities before the onset of demyelination. J Neurol Sci 110, 195-204 (1992)
38. L. Pantoni, A. Poggesi and D. Inzitari: The relation between white-matter lesions and cognition. Curr Opin Neurol 20, 390-7 (2007) (Pubitemid 47051984)
39. J. D. Schmahmann, E. E. Smith, F. S. Eichler and C. M. Filley: Cerebral white matter: neuroanatomy, clinical neurology, and neurobehavioral correlates. Ann N Y Acad Sci 1142, 266-309 (2008)
40. J. D. Hinman and C. R. Abraham: What's behind the decline? The role of white matter in brain aging. Neurochem Res 32, 2023-31 (2007) (Pubitemid 350059846)
41. L. Gootjes, S. J. Teipel, Y. Zebuhr, R. Schwarz, G. Leinsinger, P. Scheltens, H. J. Moller and H. Hampel: Regional distribution of white matter hyperintensities in vascular dementia, Alzheimer's disease and healthy aging. Dement Geriatr Cogn Disord 18, 180-8 (2004) (Pubitemid 39140369)
42. G. B. Frisoni, S. Galluzzi, L. Pantoni and M. Filippi: The effect of white matter lesions on cognition in the elderly - small but detectable. Nat Clin Pract Neurol 3, 620-7 (2007) (Pubitemid 350048228)
43. D. J. Madden, I. J. Bennett and A. W. Song: Cerebral white matter integrity and cognitive aging: contributions from diffusion tensor imaging. Neuropsychol Rev 19, 415-35 (2009)
44. M. Viana-Baptista, P. Bugalho, C. Jordao, N. Ferreira, A. Ferreira, M. Forjaz Secca, J. A. Esperanca-Pina and J. M. Ferro: Cognitive function correlates with frontal white matter apparent diffusion coefficients in patients with leukoaraiosis. J Neurol 255, 360-6 (2008)
45. R. Schmidt, K. Petrovic, S. Ropele, C. Enzinger and F. Fazekas: Progression of leukoaraiosis and cognition. Stroke 38, 2619-25 (2007) (Pubitemid 47329648)
46. M. Gallucci, I. Amicarelli, A. Rossi, P. Stratta, C. Masciocchi, B. B. Zobel, M. Casacchia and R. Passariello: MR imaging of white matter lesions in uncomplicated chronic alcoholism. J Comput Assist Tomogr 13, 395-8 (1989) (Pubitemid 19141755)
47. A. Pfefferbaum, E. V. Sullivan, M. Hedehus, E. Adalsteinsson, K. O. Lim and M. Moseley: In vivo detection and functional correlates of white matter microstructural disruption in chronic alcoholism. Alcohol Clin Exp Res 24, 1214-21 (2000) (Pubitemid 30650940)
48. M. J. Romero, S. Asensio, C. Palau, A. Sanchez and F. J. Romero: Cocaine addiction: diffusion tensor imaging study of the inferior frontal and anterior cingulate white matter. Psychiatry Res 181, 57-63 (2010)
49. Y. Feng: Convergence and divergence in the etiology of myelin impairment in psychiatric disorders and drug addiction. Neurochem Res 33, 1940-9 (2008)
50. W. E. Hogancamp, M. Rodriguez and B. G. Weinshenker: The epidemiology of multiple sclerosis. Mayo Clin Proc 72, 871-8 (1997) (Pubitemid 27382929)
51. P. Kujala, R. Portin and J. Ruutiainen: The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up. Brain 120 ( Pt 2), 289-97 (1997) (Pubitemid 27107662)
52. N. D. Chiaravalloti and J. DeLuca: Cognitive impairment in multiple sclerosis. Lancet Neurol 7, 1139-51 ( 2008)
53. H. M. Genova, J. F. Sumowski, N. Chiaravalloti, G. T. Voelbel and J. Deluca: Cognition in multiple sclerosis: a review of neuropsychological and fMRI research. Front Biosci 14, 1730-44 (2009)
54. J. A. Bobholz and S. M. Rao: Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr Opin Neurol 16, 283-8 (2003) (Pubitemid 36688294)
55. A. Feinstein, L. D. Kartsounis, D. H. Miller, B. D. Youl and M. A. Ron: Clinically isolated lesions of the type seen in multiple sclerosis: a cognitive, psychiatric, and MRI follow up study. J Neurol Neurosurg Psychiatry 55, 869-76 (1992)
56. M. J. Hohol, C. R. Guttmann, J. Orav, G. A. Mackin, R. Kikinis, S. J. Khoury, F. A. Jolesz and H. L. Weiner: Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch Neurol 54, 1018-25 (1997) (Pubitemid 27330411)
57. G. Comi, M. Rovaris, M. Falautano, G. Santuccio, V. Martinelli, M. A. Rocca, F. Possa, L. Leocani, E. Paulesu and M. Filippi: A multiparametric MRI study of frontal lobe dementia in multiple sclerosis. J Neurol Sci 171, 135-44 (1999)
58. L. A. Chwastiak and D. M. Ehde: Psychiatric issues in multiple sclero sis. Psychiatr Clin North Am 30, 803-17 (2007) (Pubitemid 47552650)
59. H. Rauschka, B. Colsch, N. Baumann, R. Wevers, M. Schmidbauer, M. Krammer, J. C. Turpin, M. Lefevre, C. Olivier, S. Tardieu, W. Krivit, H. Moser, A. Moser, V. Gieselmann, B. Zalc, T. Cox, U. Reuner, A. Tylki- Szymanska, F. Aboul-Enein, E. LeGuern, H. Bernheimer and J. Berger: Late-onset metachromatic leukodystrophy: genotype strongly influences phenotype. Neurology 67, 859-63 (2006) (Pubitemid 44394203)
60. S. H. Freeman, B. T. Hyman, K. B. Sims, E. T. Hedley- Whyte, A. Vossough, M. P. Frosch and J. D. Schmahmann: Adult onset leukodystrophy wit h neuroaxonal spheroids: clinical, neuroimaging and neuropathologic observations. Brain Pathol 19, 39-47 (2009)
61. T. M. Hyde, J. C. Ziegler and D. R. Weinberger: Psychiatric disturbances in metachromatic leu kodystrophy. Insights into the neurobiology of psychosis. Arch Neurol 49, 401-6 (1992)
62. N. Baumann, J. C. Turpin, M. Lefevre and B. Colsch: Motor and psycho-cognitive clinical types in adult m etachromatic leukodystrophy: genotype/phenotype relationships? J Physiol Paris 96, 301-6 (2002) (Pubitemid 36090368)
63. D. N. Black, K. H. Taber and R. A. Hurley: Metachromatic leukodystrophy: a model for the study of p sychosis. J Neuropsychiatry Clin Neurosci 15, 289-93 (2003) (Pubitemid 36999371)
64. T. K. Rajji, Z. Ismail and B. H. Mulsant: Age at onset and cognition in schizophrenia: meta-analysis. Br J Psychiatry 195, 286-93 (2009)
65. R. Lewis: Should cognitive deficit be a diagnostic criterion for schizophrenia? J Psychiatry Neurosci 29, 102-13 (2004) (Pubitemid 38570215)
66. J. van Os and S. Kapur: Schizophrenia. Lancet 374, 635-45 (2009)
67. V. A. Mittal, L. M. Ellman and T. D. Cannon: Geneenvironment interaction and covariation in schizophrenia: the role of obstetric complications. Schizophr Bull 34, 1083-94 (2008)
68. M. J. Minzenberg, A. R. Laird, S. Thelen, C. S. Carter and D. C. Glahn: Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psychiatry 66, 811-22 (2009)
69. J. M. Ford, J. H. Krystal and D. H. Mathalon: Neural synchrony in schizophrenia: from networks to new treatments. Schizophr Bull 33, 848-52 (2007) (Pubitemid 47216662)
70. L. D. Selemon and P. S. Goldman-Rakic: The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry 45, 17-25 (1999) (Pubitemid 29049200)
71. S. Heckers, H. Heinsen, B. Geiger and H. Beckmann: Hippocampal neuron number in schizophrenia. A stereological study. Arch Gen Psychiatry 48, 1002-8 (1991)
72. L. A. Glantz and D. A. Lewis: Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 57, 65-73 (2000) (Pubitemid 30035660)
73. N. Uranova, D. Orlovskaya, O. Vikhreva, I. Zimina, N. Kolomeets, V. Vostrikov and V. Rachmanova: Electron microscopy of oligodendroglia in severe mental illness. Brain Res Bull 55, 597-610 (2001) (Pubitemid 32888378)
74. N. A. Uranova, V. M. Vostrikov, D. D. Orlovskaya and V. I. Rachmanova: Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr Res 67, 269-75 (2004) (Pubitemid 38251458)
75. V. Vostrikov, D. Orlovskaya and N. Uranova: Deficit of pericapillary oligodendrocytes in the prefrontal cortex in schizophrenia. World J Biol Psychiatry 9, 34-42 (2008) (Pubitemid 351250518)
76. V. M. Vostrikov, N. A. Uranova and D. D. Orlovskaya: Deficit of perineuronal oligodendrocytes in the prefrontal cortex in schizophrenia and mood disorders. Schizophr Res 94, 273-80 (2007) (Pubitemid 47031593)
77. P. R. Hof, V. Haroutunian, V. L. Friedrich, Jr., W. By ne, C. Buitron, D. P. Perl and K. L. Davis: Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry 53, 1075-85 (2003) (Pubitemid 36695083)
78. A. J. Dwork, B. Mancevski and G. Rosoklija: White matter and cognitive function in schizophrenia. Int J Neuropsychopharmacol 10, 513-36 (2007) (Pubitemid 46985263)
79. M. Kubicki, H. Park, C. F. Westin, P. G. Nestor, R. V. Mulkern, S. E. Maier, M. Niznikiewicz, E. E. Connor, J. J. Levitt, M. Frumin, R. Kikinis, F. A. Jolesz, R. W. McCarley and M. E. Shenton: DTI and MTR abnormalities in schizophrenia: analysis of white matter integrity. Neuroimage 26, 1109-18 (2005) (Pubitemid 40806489)
80. M. S. Bagary, M. R. Symms, G. J. Barker, S. H. Mutsatsa, E. M. Joyce and M. A. Ron: Gray and white matter brain abnormalities in first-episode schizophrenia inferred from magnetization transfer imaging. Arch Gen Psychiatry 60, 779-88 (2003) (Pubitemid 36960909)
81. V. Cheung, C. Cheung, G. M. McAlonan, Y. Deng, J. G. Wong, L. Yip, K. S. Tai, P. L. Khong, P. Sham and S. E. Chua: A diffusion tensor imaging study of structural dysconnectivity in never-medicated, first-episode schizophrenia. Psychol Med 38, 877-85 (2008) (Pubitemid 351684593)
82. R. Gasparotti, P. Valsecchi, F. Carletti, A. Galluzzo, R. Liserre, B. Cesana and E. Sacchetti: Reduced fractional anisotropy of corpus callosum in first-contact, antipsychotic drug-naive patients with schizophrenia. Schizophr Res 108, 41-8 (2009)
83. W. Y. Chan, G. L. Yang, M. Y. Chia, I. Y. Lau, Y. Y. Sitoh, W. L. Nowinski and K. Sim: White matter abnormalities in first-episode schizophrenia: A combined structural MRI and DTI study. Schizophr Res (epub 2010)
84. R. Perez-Iglesias, D. Tordesillas-Gutierrez, P. K. McGuire, G. J. Barker, R. Roiz-Santianez, I. Mata, E. M. de Lucas, J. M. Rodriguez-Sanchez, R. Ayesa-Arriola, J. L. Vazquez-Barquero and B. Crespo-Facorro: White Matter Integrity and Cognitive Impairment in First-Episode Psychosis. Am J Psychiatry (epub 2010)
85. J. Moriya, S. Kakeda, O. Abe, N. Goto, R. Yoshimura, H. Hori, N. Ohnari, T. Sato, S. Aoki, K. Ohtomo, J. Nakamura and Y. Korogi: Gray and white matter volumetric and diffusion tensor imaging (DTI) analyses in the early stage of first-episode schizophrenia. Schizophr Res 116, 196- 203 (2010)
86. M. Kyriakopoulos, N. S. Vyas, G. J. Barker, X. A. Chitnis and S. Frangou: A diffusion tensor imaging study of white matter in early-onset schizophrenia. Biol Psychiatry 63, 519-23 (2008) (Pubitemid 351220786)
87. J. I. Friedman, C. Tang, D. Carpenter, M. Buchsbaum, J. Schmeidler, L. Flanag an, S. Golembo, I. Kanellopoulou, J. Ng, P. R. Hof, P. D. Harvey, N. D. Tsopelas, D. Stewart and K. L. Davis: Diffusion tensor imaging findings in firstepisode and chronic schizophrenia patients. Am J Psychiatry 165, 1024-32 (2008)
88. L. R. Skelly, V. Calhoun, S. A. Meda, J. Kim, D. H. Mathalon and G. D. Pearlson: Diffusion tensor imaging in schizophrenia: relationship to symptoms. Schizophr Res 98, 157-62 (2008) (Pubitemid 350235907)
89. G. Rametti, C. Junque, C. Falcon, N. Bargallo, R. Catalan, R. Penades, B. Garzon and M. Bernardo: A voxelbased diffusion tensor imaging study of temporal white matter in patients with schizophrenia. Psychiatry Res 171, 166-76 (2009)
90. B. A. Ardekani, A. Tabesh, S. Sevy, D. G. Robinson, R. M. Bilder and P. R. Szeszko: Diffusion tensor imaging reliably differentiates patients with schizophrenia from healthy volunteers. Hum Brain Mapp (epub 2010)
91. J. Camchong, K. O. Lim, S. R. Sponheim and A. W. Macdonald: Frontal white matter integrity as an endophenotype for schizophrenia: diffusion tensor imaging in monozygotic twins and patients' nonpsychotic relatives. Front Hum Neurosci 3, 35 (2009)
92. Y. Hakak, J. R. Walker, C. Li, W. H. Wong, K. L. Davis, J. D. Buxbaum, V. Haroutunian and A. A. Fienberg: Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A 98, 4746-51 (2001) (Pubitemid 32295047)
93. D. Tkachev, M. L. Mimmack, M. M. Ryan, M. Wayland, T. Freeman, P. B. Jones, M. Starkey, M. J. Webster, R. H. Yolken and S. Bahn: Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 362, 798-805 (2003) (Pubitemid 37093922)
94. T. R. Peirce, N. J. Bray, N. M. Williams, N. Norton, V. Moskvin a, A. Preece, V. Haroutunian, J. D. Buxbaum, M. J. Owen and M. C. O'Donovan: Convergent evidence for 2',3'-cyclic nucleotide 3'- phosphodiesterase as a possible susceptibility gene for schizophrenia. Arch Gen Psychiatry 63, 18-24 (2006) (Pubitemid 43040014)
95. T. Sugai, M. Kawamura, S. Iritani, K. Araki, T. Makifuchi, C. Imai, R. Nakamura, A. Kakita, H. Takahashi and H. Nawa: Prefrontal abnormality of schizophrenia revealed by DNA microarray: impact on glial and neurotrophic gene expression. Ann N Y Acad Sci 1025, 84-91 (2004) (Pubitemid 39643849)
96. S. Dracheva, K. L. Davis, B. Chin, D. A. Woo, J. Schmeidler and V. Haroutunian: Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients. Neurobiol Dis 21, 531-40 (2006) (Pubitemid 43277536)
97. C. Aston, L. Jiang and B. P. Sokolov: Microarray an alysis of postmortem temporal cortex from patients with schizophrenia. J Neurosci Res 77, 858-66 (2004) (Pubitemid 39187068)
98. K. L. Davis, D. G. Stewart, J. I. Friedman, M. Buchsbaum, P. D. Harvey, P. R. Hof, J. Buxbaum and V. Haroutunian: White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 60, 443-56 (2003) (Pubitemid 36539053)
99. V. Haroutunian, P. Katsel, S. Dracheva, D. G. Stewart and K. L. Davis: Variations in oligodendrocyte-related gene expression across multiple cortical regions: implications for the pathophysiology of schizophrenia. Int J Neuropsychopharmacol 10, 565-73 (2007) (Pubitemid 46985258)
100. P. Katsel, K. L. Davis and V. Haroutunian: Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: a gene ontology study. Schizophr Res 79, 157-73 (2005) (Pubitemid 41457256)
101. R. E. McCullumsmith, D. Gupta, M. Beneyto, E. Kreger, V. Haroutunian, K. L. Davis and J. H. Meador- Woodruff: Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia. Schizophr Res 90, 15-27 (2007) (Pubitemid 46177577)
102. B. P. Sokolov: Oligodendroglial abnormalities in schizophrenia, mood di sorders and substance abuse. Comorbidity, shared traits, or molecular phenocopies? Int J Neuropsychopharmacol 10, 547-55 (2007) (Pubitemid 46985259)
103. C. Aston, L. Jiang and B. P. Sokolov: Transcriptional profiling re veals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol Psychiatry 10, 309-22 (2005) (Pubitemid 40432684)
104. C. Demerens, B. Stankoff, M. Logak, P. Anglade, B. Allinquant, F. Couraud, B. Zalc and C. Lubetzki: Induction of myelination in the central nervous system by electrical activity. Proc Natl Acad Sci U S A 93, 9887-92 (1996) (Pubitemid 26296704)
105. B. E. Snitz, A. MacDonald, 3rd, J. D. Cohen, R. Y. Cho, T. Becker and C. S. Carter: Lateral and medial hypofrontality in first-episode schizophrenia: functional activity in a medication-naive state and effects of shortterm atypical antipsychotic treatment. Am J Psychiatry 162, 2322-9 (2005) (Pubitemid 41740211)
106. E. E. Benarroch: Oligodendrocytes: Susceptibility to injury and involvement in neurologic disease. Neurology 72, 1779-85 (2009)
107. J. T. Coyle: Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26, 365-84 (2006)
108. C. Konradi and S. Heckers: Molecular a spects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther 97, 153-79 (2003) (Pubitemid 36138820)
109. C. G. Hahn, H. Y. Wang, D. S. Cho, K. Talbot, R. E. Gur, W. H. Berrettini, K. Bakshi, J. Kamins, K. E. Borgmann-Winter, S. J. Siegel, R. J. Gallop and S. E. Arnold: Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 12, 824-8 (2006) (Pubitemid 44050073)
110. T. Li, H. Stefansson, E. Gudfinnsson, G. Cai, X. Liu, R. M. Murray, V. Steinthorsdottir, D. Januel, V. G. Gudnadottir, H. Petursson, A. Ingason, J. R. Gulcher, K. Stefansson and D. A. Collier: Identification of a novel neuregulin 1 at-risk haplotype in Han schizophrenia Chinese patients, but no association with the Icelandic/Scottish risk haplotype. Mol Psychiatry 9, 698-704 (2004) (Pubitemid 38932174)
111. H. Jaaro-Peled, A. Hayashi-Takagi, S. Seshadri, A. Kamiya, N. J. Brandon and A. Sawa: Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1. Trends Neurosci 32, 485-95 (2009)
112. A. Konrad, G. Vucurevic, F. Musso, P. Stoeter, N. Dahmen and G. Winterer: ErbB4 genotype predicts left frontotemporal structural connectivity in human brain. Neuropsychopharmacology 34, 641-50 (2009)
113. B. A. Barres: The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 60, 430-40 (2008)
114. K. A. Nave and J. L. Salzer: Axonal regulation of myelination by neuregulin 1. Curr Opin Neurobiol 16, 492-500 (2006) (Pubitemid 44466397)
115. C. Taveggia, G. Zanazzi, A. Petrylak, H. Yano, J. Rosenbluth, S. Einheber, X. Xu, R. M. Esper, J. A. Loeb, P. Shrager, M. V. Chao, D. L. Falls, L. Role and J. L. Salzer: Neuregulin-1 type III determines the ensheathment fate of axons. Neuron 47, 681-94 (2005) (Pubitemid 41208007)
116. D. St Clair, D. Blackwood, W. Muir, A. Carothers, M. Walker, G. Spowart, C. Gosden and H. J. Evans: Association within a family of a balanced autosomal translocation with major mental illness. Lancet 336, 13-6 (1990) (Pubitemid 20207869)
117. J. K. Millar, J. C. Wilson-Annan, S. Anderson, S. Christie, M. S. Taylor, C. A. Semple, R. S. Devon, D. M. St Clair, W. J. Muir, D. H. Blackwood and D. J. Porteous: Disruption of two novel genes by a translocation cosegregating with schizophrenia. Hum Mol Genet 9, 1415-23 (2000) (Pubitemid 30312490)
118. J. D. Wood, F. Bonath, S. Kumar, C. A. Ross and V. T. Cunliffe: Disrupted-in-schizophrenia 1 and neureg ulin 1 are required for the specification of oligodendrocytes and neurones in the zebrafish brain. Hum Mol Genet 18, 391-404 (2009)
119. X. Duan, J. H. Chang, S. Ge, R. L. Faulkner, J. Y. Kim, Y. Kitabatake, X. B. Liu, C. H. Yang, J. D. Jordan, D. K. Ma, C. Y. Liu, S. Ganesan, H. J. Cheng, G. L. Ming, B. Lu and H. Song: Disrupted-In-Schizophrenia 1 regulates integration of newly generated neurons in the adult brain. Cell 130, 1146-58 (2007) (Pubitemid 47422304)
120. S. Kim and M. J. Webster: The stanley neuropathology consortium integrative database: a novel, web-based tool for exploring neuropathological markers in psy chiatric disorders and the biological processes associated with abnormalities of those markers. Neuropsychopharmacology 35, 473-82 (2010)
121. F. Impagnatiello, A. R. Guidotti, C. Pesold, Y. Dwi vedi, H. Caruncho, M. G. Pisu, D. P. Uzunov, N. R. Smalheiser, J. M. Davis, G. N. Pandey, G. D. Pappas, P. Tueting, R. P. Sharma and E. Costa: A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc Natl Acad Sci U S A 95, 15718-23 (1998) (Pubitemid 29018766)
122. S. H. Fatemi, J. A. Earle and T. McMenomy: Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression. Mol Psychiatry 5, 654- 63, 571 (2000)
123. D. R. Grayson, X. Jia, Y. Chen, R. P. Sharma, C. P. Mitchell, A. Guidotti and E. Costa: Reelin pr omoter hypermethylation in schizophrenia. Proc Natl Acad Sci U S A 102, 9341-6 (2005)
124. R. Panteri, J. Mey, N. Zhelyaznik, A. D'Altocolle, A. Del Fa, C. Gangitano, R. Marino, E. Lorenzetto, M. Buffelli and F. Keller: Reelin is transiently expressed in the peripheral nerve during development and is upregulated following nerve crush. Mol Cell Neurosci 32, 133-42 (2006) (Pubitemid 43868102)
125. G. D'Arcangelo, G. G. Miao, S. C. Chen, H. D. Soares, J. I. Morgan and T. Curran: A protein related to extracellular matrix proteins deleted in the mouse mutant reeler. Nature 374, 719-23 (1995)
126. K. Ono, H. Takebayashi and K. Ikenaka: Olig2 transcription factor in the developing and injured forebrain; cell lineage and glial development. Mol Cells 27, 397-401 (2009)
127. L. Georgieva, V. Moskvina, T. Peirce, N. Norton, N. J. Bray, L. Jones, P. Holmans, S. Macgregor, S. Zammit, J. Wilkinson, H. Williams, I. Nikolov, N. Williams, D. Ivanov, K. L. D avis, V. Haroutunian, J. D. Buxbaum, N. Craddock, G. Kirov, M. J. Owen and M. C. O'Donovan: Convergent evidence that oligodendrocyte lineage transcription factor 2 (OLIG2) and interacting genes influence susceptibility to schizophrenia. Proc Natl Acad Sci U S A 103, 12469-74 (2006) (Pubitemid 44267283)
128. K. Huang, W. Tang, R. Tang, Z. Xu, Z. He, Z. Li, Y. Xu, X. Li, G. He, G. Feng, L. He and Y. Shi: Positive association between OLIG2 and schizophrenia in the Chinese Han population. Hum Genet 122, 659-60 (2008)
129. H. Usui, N. Takahashi, S. Saito, R. Ishihara, N. Aoyama, M. Ikeda, T. Suzuki, T. Kitajima, Y. Yamanouchi, Y. Kinoshita, K. Yoshida, N. Iwata, T. Inada and N. Ozaki: The 2',3'-cyclic nucleotide 3'- phosphodiesterase and oligodendrocyte lineage transcription factor 2 genes do not appear to be associa ted with schizophrenia in the Japanese population. Schizophr Res 88, 245-50 (2006) (Pubitemid 44693254)
130. M. Neves-Pereira, J. K. Cheung, A. Pasdar, F. Zhang, G. Breen, P. Yates, M. Sinclair, C. Crombie, N. Walker and D. M. St Clair: BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol Psychiatry 10, 208-12 (2005) (Pubitemid 40188515)
131. R. D. Jindal, A. K. Pillai, S. P. Mahadik, K. Eklund, D. M. Montrose and M. S. Keshavan: Decreased BDNF in patients with antipsychotic naive first episode schizophrenia. Schizophr Res (epub 2010)
132. J. K. Rybakowski: BDNF gene: functional Val66Met polymorphism in mood disorders and schizophrenia. Pharmacogenomics 9, 1589-93 (2008)
133. J. K. Rybakowski, A. Borkowska, M. Skibinska and J. Hauser: Illness-specific association of val66met BDNF polymorphism with performance on Wisconsin Card Sorting Test in bipolar mood disorder. Mol Psychiatry 11, 122-4 (2006) (Pubitemid 43164612)
134. J. Xu, Y. Liu, P. Wang, S. Li, Y. Wang, J. Li, D. Zhou, Z. Chen, T. Zhao, T. Wang, H. Xu, Y. Yang, G. Feng, L. He and L. Yu: Positive association between the brain-derived neurotrophic factor (BDNF) gene and bipolar disorder in the Han Chinese population. Am J Med Genet B Neuropsychiatr Genet 153B, 275-9 (epub 2010)
135. A. Palomino, A. Vallejo-Illarramendi, A. Gonzalez- Pinto, A. Aldama, C. Gonzalez-Gomez, F. Mosquera, G. Gonzalez-Garcia and C. Matute: Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr Res 86, 321-2 (2006) (Pubitemid 44234056)
136. F. W. Lohoff, T. Sander, T. N. Ferraro, J. P. Dahl, J. Gallinat and W. H. Berrettini: Confirmation of association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and bipolar I disorder. Am J Med Genet B Neuropsychiatr Genet 139B, 51-3 (2005) (Pubitemid 41552298)
137. T. Okada, R. Hashimoto, T. Numakawa, Y. Iijima, A. Kosuga, M. Tatsumi, K. Kamijima, T. Kato and H. Kunugi: A complex polymorphic region in the brain-derived neurotrophic factor (BDNF) gene confers susceptibility to bipolar disorder and affects transcriptional activity. Mol Psychiatry 11, 695-703 (2006) (Pubitemid 43989816)
138. A. Rosa, M. J. Cuesta, M. Fatjo-Vilas, V. Peralta, A. Zarzuela and L. Fananas: The Val66Met polymorphism of the brain-derived neurotrophic factor gene is associated with risk for psychosis: evidence from a family-based association study. Am J Med Genet B Neuropsychiat r Genet 141B, 135-8 (2006) (Pubitemid 43214787)
139. A. Squassina, P. Piccardi, M. Del Zompo, A. Rossi, A. Vita, S. Pini, A. Mucci and S. Galderisi: NRG1 and BDNF genes in schizophrenia: An association study in an Italian case-control sample. Psychiatry Res 176, 82-84 (epub 2010)
140. K. Kawashima, M. Ikeda, T. Kishi, T. Kitajima, Y. Yamanouchi, Y. Kinoshita, T. Okochi, B. Aleksic, M. Tomita, T. Okada, H. Kunugi, T. Inada, N. Ozaki and N. Iwata: BDNF is not associated with schizophrenia: data from a Japanese population study and meta-analysis. Schizophr Res 112, 72-9 (2009)
141. M. W. Vondran, P. Clinton-Luke, J. Z. Honeywell and C. F. Dreyfus: BDNF+/- mice exhibit deficits in oligodendrocyte lineage cells of the basal forebrain. Glia (epub 2010)
142. Y. Du, T. Z. Fischer, L. N. Lee, L. D. Lercher and C. F. Dreyfus: Regionally specific effects of BDNF on oligodendrocytes. Dev Neurosci 25, 116-26 (2003) (Pubitemid 37100207)
143. S. Heng, A. W. Song and K. Sim: White matter abno rmalities in bipolar disorder: insights from diffusion tensor imaging studies. J Neural Transm (epub 2010)
144. K. Mahon, K. E. Burdick and P. R. Szeszko: A role for white matter abnormalities in the pathophysi ology of bipolar disorder. Neurosci Biobehav Rev 34, 533-54 (2010)
145. D. N. Albertson, B. Pruetz, C. J. Schmidt, D. M. Kuhn, G. Kapatos and M. J. Bannon: Gene expression profile o f the nucleus accumbens of human cocaine
146. J. S. Oh, I. K. Lyoo, Y. H. Sung, J. Hwang, J. Kim, A. Chung, K. S. Park, S. J. Kim, P. F. Renshaw and I. C. Song: Shape changes of the corpus callosum in abstinent methamphetamine users. Neurosci Lett 384, 76-81 (2005) (Pubitemid 40826621)
147. G. Bartzokis, M. Beckson, P. H. Lu, N. Edwards, R. Rapoport, E. Wiseman and P. Bridge: Age-related brain volume reductions in amphetamine and cocaine addicts and normal controls: implications for addiction research. Psychiatry Res 98, 93-102 (2000) (Pubitemid 30179661)
148. L. Chang, C. Cloak, K. Patterson, C. Grob, E. N. Miller and T. Ernst: Enlarged striatum in abstinent methamphetamine abusers: a possible compensatory response. Biol Psychiatry 57, 967-74 (2005) (Pubitemid 40603079)
149. P. M. Thompson, K. M. Hayashi, S. L. Simon, J. A. Geaga, M. S. Hong, Y. Sui, J. Y. Lee, A. W. Toga, W. Ling and E. D. London: Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci 24, 6028-36 (2004) (Pubitemid 38859399)
150. M. C. Tobias, J. O'Neill, M. Hudkins, G. Bartzokis, A. C. Dean and E. D. London: White-matter abnormalities in brain during early abstinence from methamphetamine abuse. Psychopharmacology (Berl) 209, 13-24 (2010)
151. K. Baicy and E. D. London: Corticolimbic dysregulation and chronic methamphetamine abuse. Addiction 102 Suppl 1, 5-15 (2007) (Pubitemid 46328215)
152. A. M. Barr, W. J. Panenka, G. W. MacEwan, A. E. Thornton, D. J. Lang, W. G. Honer and T. Lecomte: The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci 31, 301-13 (2006) (Pubitemid 44497427)
153. C. W. Meredith, C. Jaffe, K. Ang-Lee and A. J. Saxon: Implications of chronic methamphetamine use: a literature review. Harv Rev Psychiatry 13, 141-54 (2005) (Pubitemid 40967247)
154. S. Darke, S. Kaye, R. McKetin and J. Duflou: Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev 27, 253-62 (2008)
155. A. D. Kalechstein, T. F. Newton, D. Longshore, M. D. Anglin, W. G. van Gorp and F. H. Gawin: Psychiatric comorbidity of methamphetamine dependence in a forensic sample. J Neuropsychiatry Clin Neurosci 12, 480-4 (2000)
156. A. M. Leventhal, C. W. Kahler, L. A. Ray, K. Stone, D. Young, I. Chelminski and M. Zimmerman: Anhedonia and amotivation in psychiatric outpatients with fully remitted stimulant use disorder. Am J Addict 17, 218-23 (2008) (Pubitemid 351883190)
157. L. Messori, A. Casini, C. Gabbiani, L. Sorace, M. Muniz- Miranda and P. Zatta: Unravelling the chemical nature of copper cuprizone. Dalton Trans, 2112-4 (2007) (Pubitemid 46791128)
158. P. Zatta, M. Raso, P. Zambenedetti, W. Wittkowski, L. Messori, F. Piccioli, P. L. Mauri and M. Beltramini: Copper and zinc dismetabolism in the mouse brain upon chronic cuprizone treatment. Cell Mol Life Sci 62, 1502-13 (2005) (Pubitemid 40922952)
159. J. R. Gregg, N. R. Herring, A. Naydenov, R. P. Hanlin and C. Konradi: Downregulation of oligodendrocyte transcripts is associated with impaired prefrontal cortex function in rats. Schizophr Res (2009)
160. B. E. Kim, T. Nevitt and D. J. Thiele: Mechanisms for copper acquisition, distribution and regulation. Nat Chem Biol 4, 176-85 (2008) (Pubitemid 351264130)
161. C. Andreini, L. Banci, I. Bertini and A. Rosato: Occurrence of copper proteins through the three domains of life: a bioinformatic approach. J Proteome Res 7, 209-16 (2008) (Pubitemid 351171133)
162. I. Fridovich: Superoxide dismutases. Annu Rev Biochem 44, 147-59 (1975)
163. X. Zhang and W. S. McIntire: Cloning and sequencing of a copper-containing, topa quinone-containing monoamine oxidase from human placenta. Gene 179, 279-86 (1996) (Pubitemid 26397704)
164. N. J. Blackburn, H. S. Mason and P. F. Knowles: Dopamine-beta- hydroxylase: evidence for binuclear copper sites. Biochem Biophys Res Commun 95, 1275-81 (1980)
165. D. Horn and A. Barrientos: Mitochondrial copper metabolism and delivery to cytochrome c oxidase. IUBMB Life 60, 421-9 (2008)
166. Y. Takahashi, K. Kako, S. Kashiwabara, A. Takehara, Y. Inada, H. Arai, K. Nakada, H. Kodama, J. Hayashi, T. Baba and E. Munekata: Mammalian copper chaperone Cox17p has an essential role in activation of cytochrome C oxidase and embryonic development. Mol Cell Biol 22, 7614-21 (2002)
167. M. D. Harrison, C. E. Jones, M. Solioz and C. T. Dameron: Intracellular copper routing: the role of copper chaperones. Trends Biochem Sci 25, 29-32 (2000) (Pubitemid 30060427)
168. S. Puig and D. J. Thiele: Molecular mechanisms of copper uptake and distribution. Curr Opin Chem Biol 6, 171-80 (2002) (Pubitemid 34251372)
169. W. W. Carlton: Studies on the induction of hydrocephalus and spongy degeneration by cuprizone feeding and attempts to antidote the toxicity. Life Sci 6, 11-9 (1967)
170. G. K. Matsushima and P. Morell: The neurotoxicant, cuprizone, as a model to study demy elination and remyelination in the central nervous system. Brain Pathol 11, 107-16 (2001)
171. S. A. K. Wilson: Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain 34, 295-507 (1912)
172. P. de Bie, P. Muller, C. Wijmenga and L. W. Klomp: Molecular pathogenesis of Wilson and Menkes disease: correlation of mutations with molecular defects and disease phenotypes. J Med Genet 44, 673-88 (2007) (Pubitemid 350161581)
173. H. N. van Wassenaer-van Hall, A. G. van den Heuvel, G. H. Jansen, T. U. Hoogenraad and W. P. Mali: Cranial MR in Wilson disease: abnormal white matter in extrapyramidal and pyramidal tracts. AJNR Am J Neuroradiol 16, 2021-7 (1995)
174. K. Srinivas, S. Sinha, A. B. Taly, L. K. Prashanth, G. R. Arunodaya, Y. C. Janardhana Reddy and S. Khanna: Dominant psychiatric manifestations in Wilson's disease: a diagnostic and therapeutic challenge! J Neurol Sci 266, 104-8 (2008) (Pubitemid 351186530)
175. H. M. Wichowicz, W. J. Cubala and J. Slawek: Wilson's disease associated with delusional disorder. Psychiatry Clin Neurosci 60, 758-60 (2006) (Pubitemid 44736602)
176. T. R. Dening: Psychiatric aspects of Wilson's disease. Br J Psychiatry 147, 677-82 (1985) (Pubitemid 16175711)
177. J. R. Prohaska and T. L. Smith: Effect of dietary or genetic copper deficiency on brain catecholamines, trace metals and enzymes in mice and rats. J Nutr 112, 1706-17 (1982) (Pubitemid 13246888)
178. J. H. Menkes, M. Alter, G. K. Steigleder, D. R. Weakley and J. H. Sung: A sex-linked recessive disorder with retardation of growth, peculiar hair, and focal cerebral and cerebellar degeneration. Pediatrics 29, 764-79 (1962)
179. R. O. Barnard, P. V. Best and M. Erdohazi: Neuropathology of Menkes' disease. Dev Med Child Neurol 20, 586-97 (1978) (Pubitemid 9042886)
180. L. Vagn-Hansen, E. Reske-Nielsen and H. C. Lou: Menkes' disease - a new leucodystrophy (?). A clinical and neuropathological review together with a new case. Acta Neuropathol 25, 103-19 (1973)
181. P. C. Liu, Y. W. Chen, J. A. Centeno, M. Quezado, K. Lem and S. G. Kaler: Downregulation of myelination, energy, and translational genes in Menkes disease brain. Mol Genet Metab 85, 291-300 (2005) (Pubitemid 41074113)
182. S. G. Kaler, C. S. Holmes, D. S. Goldstein, J. Tang, S. C. Godwin, A. Donsante, C. J. Liew, S. Sato and N. Patronas: Neonatal diagnosis and treatment of Menkes disease. N Engl J Med 358, 605-14 (2008) (Pubitemid 351214287)
183. L. Heilmeyer, W. Keiderling and C. Struve: Kupfer und Eisen als koerpereigene Wirkstoffe und ihre Bedeutung beim Krankheitsgeschehen. Fischer, Jena (1941)
184. M. B. Bowman and M. S. Lewis: The copper hypothesis of schizophrenia: a review. Neurosci Biobehav Rev 6, 321-8 (1982) (Pubitemid 13254308)
185. M. Yanik, A. Kocyigit, H. Tutkun, H. Vural and H. Herken: Plasma manganese, selenium, zinc, copper, and iron concentrations in patients with schizophrenia. Biol Trace Elem Res 98, 109-17 (2004) (Pubitemid 38608546)
186. D. A. Olatunbosun, M. O. Akindele, B. K. Adadevoh and T. Asuni: Serum copper in schizophrenia in Nigerians. Br J Psychiatry 127, 119-21 (1975)
187. A. Rahman, M. A. Azad, I. Hossain, M. M. Qusar, W. Bari, F. Begum, S. M. Huq and A. Hasnat: Zinc, manganese, calcium, copper, and cadmium level in scalp hair samples of schizophrenic patients. Biol Trace Elem Res 127, 102-8 (2009)
188. D. Shore, S. G. Potkin, D. R. Weinberger, E. F. Torrey, R. I. Henkin, R. P. Agarwal, J. C. Gillin and R. J. Wyatt: CSF copper concentrations in chronic schizophrenia. Am J Psychiatry 140, 754-7 (1983) (Pubitemid 13094142)
189. J. Kornhuber, K. W. Lange, P. Kruzik, W. D. Rausch, E. Gabriel, K. Jellinger and P. Riederer: Iron, copper, zinc, magnesium, and calcium in postmortem brain tissue from schizophrenic patients. Biol Psychiatry 36, 31-4 (1994) (Pubitemid 24210121)
190. K. Tada, Y. Nogami, M. Nagashima, T. Nagase, H. Ishiwata, Y. Motegi and M. Ikeda: Trace elements in the hair of schizophrenics. Biol Psychiatry 21, 325-8 (1986) (Pubitemid 16039066)
191. A. Herran, M. T. Garcia-Unzueta, M. D. Fernandez- Gonzalez, J. L. Vazquez-Barquero, C. Alvarez and J. A. Amado: Higher levels of serum copper in schizophrenic patients treated with depot neuroleptics. Psychiatry Res 94, 51-8 (2000) (Pubitemid 30224453)
192. D. Gitlin and C. A. Janeway: Turnover of the copper and protein moieties of ceruloplasmin. Nature 185, 693 (1960)
193. K. R. Zahs, V. Bigornia and C. F. Deschepper: Characterization of " plasma proteins" secreted by cultured rat macroglial cells. Glia 7, 121-33 (1993)
194. L. W. Klomp and J. D. Gitlin: Expression of the cerulo plasmin gene in the human retina and brain: implications for a pathogenic model in aceruloplasminemia. Hum Mol Genet 5, 1989-96 (1996) (Pubitemid 26413644)
195. A. G. Alias, N. Vijayan, D. S. Nair and M. Sukumaran: S erum ceruloplasmin in schizophrenia: significant increase in acute cases especially in catatonia. Biol Psychiatry 4, 231-8 (1972)
196. T. L. Wolf, J. Kotun and J. H. Meador-Woodruff: Plasma copper, iron, ceruloplasmin and ferroxidase activity in schizophrenia. Schizophr Res 86, 167-71 (2006) (Pubitemid 44234055)
197. L. C. Taylor, W. Gilmore and G. K. Matsushima: SJL mice exposed to cuprizone intoxication reveal strain and gender pattern differences in demyelination. Brain Pathol 19, 467-79 (2009)
198. T. Skripuletz, M. Lindner, A. Kotsiari, N. Garde, J. Fokuhl, F. Linsmeier, C. Trebst and M. Stangel: Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent. Am J Pathol 172, 1053-61 (2008) (Pubitemid 351520001)
199. V. Gudi, D. Moharregh-Khiabani, T. Skripuletz, P. N. Koutsoudaki, A. Kotsiari, J. Skuljec, C. Trebst and M. Stangel: Regional differences between grey and white matter in cuprizone induced demyelination. Brain Res 1283, 127-38 (2009)
200. K. Hoffmann, M. Lindner, I. Groticke, M. Stangel and W. Loscher: Epileptic seizures and hippocampal damage after cuprizone-induced demyelination in C57BL/6 mice. Exp Neurol 210, 308-21 (2008)
201. P. N. Koutsoudaki, T. Skripuletz, V. Gudi, D. Moharregh- Khiabani, H. Hildebrandt, C. Trebst and M. Stangel: Demyelination of the hippocampus is prominent in the cuprizone model. Neurosci Lett 451, 83-8 (2009)
202. A. Norkute, A. Hieble, A. Braun, S. Johann, T. Clarner, W. Baumgartner, C. Beyer and M. Kipp: Cuprizone treatment induces demyelination and astrocytosis in the mouse hippocampus. J Neurosci Res 87, 1343-55 (2009)
203. A. Groebe, T. Clarner, W. Baumgartner, J. Dang, C. Beyer and M. Kipp: Cuprizone treatm ent induces distinct demyelination, astrocytosis, and microglia cell invasion or proliferation in the mouse cerebellum. Cerebellum 8, 163-74 (2009)
204. S. K. Ludwin: Central nervous system demyelination and remyelination in the mouse: an ultrastructural study of cuprizone toxicity. Lab Invest 39, 597-612 (1978) (Pubitemid 9080664)
205. T. Skripuletz, J. H. Bussmann, V. Gudi, P. N. Koutsoudaki, R. Pul, D. Moharregh-Khiabani, M. Lindner and M. Stangel: Cerebellar Cortical Demyelination in the Murine Cuprizone Model. Brain Pathol (2009)
206. P. Morell, C. V. Barrett, J. L. Mason, A. D. Toews, J. D. Hostettler, G. W. Knapp and G. K. Matsushima: Gene expression in brain during cuprizone-induced demyelination and remyelination. Mol Cell Neurosci 12, 220-7 (1998) (Pubitemid 28536075)
207. L. A. Pasquini, C. A. Calatayud, A. L. Bertone Una, V. Millet, J. M. Pasquini and E. F. Soto: The neurotoxic effect of cuprizone on oligodendrocytes depends on the presence of pro-inflammatory cytokines secreted by microglia. Neurochem Res 32, 279-92 (2007) (Pubitemid 46238874)
208. C. Seiwa, M. Yamamoto, K. Tanaka, M. Fukutake, T. Ueki, S. Takeda, R. Sakai, A. Ishige, K. Watanabe, M. Akita, T. Yagi and H. Asou: Restoration of FcRgamma/Fyn signaling repairs central nervous system demyelination. J Neurosci Res 85, 954-66 (2007) (Pubitemid 46580337)
209. W. Cammer: The neurotoxicant, cuprizone, retards the differentiation of oligodendrocytes in vitro. J Neurol Sci 168, 116-20 (1999) (Pubitemid 29467428)
210. G. Venturini: Enzymic activities and sodium, potassium and copper concentrations in mouse brain and liver after cuprizone treatment in vivo. J Neurochem 21, 1147-51 (1973)
211. C. L. Hoppel and B. Tandler: Biochemical effects of cuprizone on mouse liver and heart mitochondria. Biochem Pharmacol 22, 2311-8 (1973)
212. R. C. Armstrong, T. Q. Le, N. C. Flint, A. C. Vana and Y. X. Zhou: Endogenous cell repair of chronic demyelination. J Neuropathol Exp Neurol 65, 245-56 (2006)
213. M. Lindner, J. Fokuhl, F. Linsmeier, C. Trebst and M. Stangel: Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination. Neurosci Lett 453, 120-5 (2009)
214. N. Franco-Pons, M. Torrente, M. T. Colomina and E. Vilella: Behavioral deficits in the cuprizone-induced murine model of demyelination/remyelination. Toxicol Lett 169, 205-13 (2007) (Pubitemid 46436370)
215. N. Hibbits, R. Pannu, T. John Wu and R. C. Armstrong: Cuprizone demyelination of the corpus callosum in mice correlates with altered social interaction and impaired bilateral sensorimotor coordination. ASN Neuro 1 (2009)
216. D. Liebetanz and D. Merkler: Effects of commissural de- and remyelination on motor skill behaviour in the cuprizone mouse model of multiple sclerosis. Exp Neurol 202, 217-24 (2006) (Pubitemid 44344263)
217. H. Xu, H. J. Yang, Y. Zhang, R. Clough, R. Browning and X. M. Li: Behavioral and neurobiological changes in C57BL/6 mice exposed to cuprizone. Behav Neurosci 123, 418-29 (2009)
218. L. Xiao, H. Xu, Y. Zhang, Z. Wei, J. He, W. Jiang, X. Li, L. E. Dyck, R. M. Devon, Y. Deng and X. M. Li: Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol Psychiatry 13, 697-708 (2008) (Pubitemid 351861531)
219. B. I. Turetsky, M. E. Calkins, G. A. Light, A. Olincy, A. D. Radant and N. R. Swerdlow: Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull 33, 69-94 (2007) (Pubitemid 46026260)
220. H. Xu, H. Yang, B. McConomy, R. Browning and X.- M. Li: Behavioral and neurobiological changes in C57BL/6 mouse exposed to cuprizone: effects of antipsychotics. Frontiers in Behavioral Neuroscience 4 (epub 2010)
221. E. Brunet-Gouet and J. Decety: Social brain dysfunctions in schizophrenia: a review of neuroimaging studies. Psychiatry Res 148, 75-92 (2006) (Pubitemid 44750585)
222. M. Makinodan, T. Yamauchi, K. Tatsumi, H. Okuda, T. Takeda, K. Kiuchi, M. Sadamatsu, A. Wanaka and T. Kishimoto: Demyelination in the juvenile period, but not in adulthood, leads to long-lasting cognitive impairment and deficient social interaction in mice. Prog Neuropsychopharmacol Biol Psychiatry 33, 978-85 (2009)
223. A. M. Adamo, P. M. Paez, O. E. Escobar Cabrera, M. Wolfson, P. G. Franco, J. M. Pasquini and E. F. Soto: Remyelination after cuprizone-induced demyelination in the rat is stimulated by apotransferrin. Exp Neurol 198, 519-29 (2006)
224. S. Love: Cuprizone neurotoxicity in the rat: morphologic observations. J Neurol Sci 84, 223-37 (1988) (Pubitemid 18087265)
225. D. C. Purves, I. J. Garrod and A. D. Dayan: A comparison of spongiosis induced in the brain by hexachlorophene, cuprizone and triethyl tin in the Sprague- Dawley rat. Hum Exp Toxicol 10, 439-44 (1991)
226. H. B. Uylings, H. J. Groenewegen and B. Kolb: Do rats have a prefrontal cortex? Behav Brain Res 146, 3-17 (2003) (Pubitemid 37476129)
227. H. B. Uylings and C. G. van Eden: Qualitative and quantitative comparison of the prefrontal cortex in ra t and in primates, including humans. Prog Brain Res 85, 31-62 (1990)
228. J. M. Birrell and V. J. Brown: Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 20, 4320-4 (2000) (Pubitemid 30365702)
229. P. D. Harvey, M. F. Green, R. S. Keefe and D. I. Velligan: Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry 65, 361-72 (2004)
230. M. F. Green, R. S. Kern, D. L. Braff and J. Mintz: Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff" ? Schizophr Bull 26, 119-36 (2000) (Pubitemid 30317696)
231. R. Emsley, B. Chiliza and R. Schoeman: Predictors of long-term outcome in schizophrenia. Curr Opin Psychiatry 21, 173-7 (2008) (Pubitemid 351339873)
232. K. Tomida, N. Takahashi, S. Saito, N. Maeno, K. Iwamoto, K. Yoshida, H. Kimura, T. Iidaka and N. Ozaki: Relationship of psychopathological symptoms and cognitive function to subjective quality of life in patients with chronic schizophrenia. Psychiatry Clin Neurosci (2009)
233. P. Franke, W. Maier, C. Hain and T. Klingler: Wisconsin Card Sorting Test: an indicator of vulnerability to schizophrenia? Schizophr Res 6, 243-9 (1992)
234. M. W. Haut, J. Cahill, W. D. Cutlip, J. M. Stevenson, E. H. Makela and S. M. Bloomfield: On the nature of Wisconsin Card Sorting Test performance in schizophrenia. Psychiatry Res 65, 15-22 (1996) (Pubitemid 26387209)
235. K. McAlonan and V. J. Brown: Orbital prefrontal cortex mediates reversal learning and not attentional set shifting in the rat. Behav Brain Res 146, 97-103 (2003) (Pubitemid 37476137)